Leukemia

Over 20 Clinical Trials Are Underway With Arsenic Trioxide

Published in Drug Week, April 6th, 2001

Cell Therapeutics, Inc. (CTIC) continues to advance the investigation of Trisenox (arsenic trioxide) injection in the treatment of a variety of blood-related cancers.

Recently-initiated studies include first-line treatment of patients with acute promyelocytic leukemia (APL) and treatment of patients with preleukemic syndromes called myelodysplasia (MDS).

"There is a growing scientific basis for investigating Trisenox in a variety of blood-related cancers and strong interest among leading hematologists to study Trisenox in diseases such as leukemia, MDS, and multiple myeloma," stated James A. Bianco, MD, Cell Therapeutics. "Combined with the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry